Synergetics has announced that it has received an additional patent covering its bipolar technology through the issuance of U.S. patent number 7,041,096. This patent will provide protect
Mylan Laboratories has announced that U.S. Patent No. 7,070,808 was issued to its subsidiary, Mylan Technologies Inc. (MTI), on July 4, 2006. The '808 Patent contains one or more claims which cov
The Munich-based drug discovery and development company 4SC AG has been informed by the US Patent and Trademark Office (PTO) that the office has granted the patent with the US patent number 7,071,355.
Respironics, Inc. has announced that it has decided to expand its relationship with Masimo and to adopt Masimo's pulse oximetry solution for situa
Pfizer Inc said today that a panel of the Court of Appeals for the Federal Circuit has upheld the exclusivity of the main patent covering atorvastatin, the active ingredient in Lipitor, maintaining pat
SRU Biosystems, Inc. announced today that in connection with the patent litigation brought by Corning Incorporated and Artificial Sensing Instruments ASI AG, the United States District Court for
Novo Nordisk has announced that the company filed a lawsuit against Pfizer claiming that Pfizer's product Exubera infringes patents owned by Novo Nordisk. The patents cover inhaled insulin treatme
Ranbaxy announced today that the U.S. Court of Appeals for the Federal Circuit (CAFC) handed down a judgment in its case challenging two key atorvastatin patents held by Pfizer. Atorvastatin is
Oragenics has announced that the US Patent office has issued a fourth patent (No. 7,067,125), that further describes the composition and uses of the company's exclusively licensed novel antibiotic p
Rapid analysis and response in the very early stages of a pandemic or bioterrorism event can sharply limit its deadly impact. Surprisingly, a key early warning sensor for biologically- related illnesses may be the human body itself and American
One of the genes is involved in protein transport within the cell. Although there is no drug yet for this gene, GenoMed believes that testing for the presence of the variant could help by identifying cancer at an earlier stage when treatment is more likely to be effective. The gene can also act as a warning sign so individuals who possess this gene variant could be monitored more closely for the development of the cancer.
The second gene is involved in signaling by a well-known hormone. It is possible that clinical trials of this gene could start in the near future. GenoMed is pursuing collaborative agreements with oncologists and their patients in order to start clinical trials. Since the therapy involves an existing drug, the process of conducting trials will be simpler than if a new drug were involved.
"These two additional genes suggest immediate next steps to be taken," said Dr. David Moskowitz, GenoMed chief executive officer and chief medical officer. "We will be making an effort to replicate the results we've achieved with a larger sample population and beginning to use these genes as early- warning signs. We will identify patients who have this gene and who have some family history of the cancers involved. We believe that they will welcome the opportunity to be monitored for the development of cancers they have a higher- than-normal probability of contracting."
"Our lab continues to identify genes linked to cancer. We soon expect to receive data from testing tens of thousands of genes at a time through our collaboration with Genome Quebec, one of the largest genomics research centers in North America. These data should allow us to identify more genes linked to various diseases over time.
"As we proceed, we believe that greater notice of our work will be taken by both patients and medical professionals. This, in turn should lead to both a greater awareness of our technology and an acceleration of the development of GenoMed as a company. While it is too soon to predict what impact the identification of these and other genes may have in terms of revenues and earnings, a 1999 article in The Wall Street Journal cited Daniel Cohen as estimating the value of a single disease-linked gene at $40-80 million" Moskowitz added.
http://www.genomedics.com/